Vimarsana
Biggest News Aggregation in the World

Page 6 - Timothy Ko News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Timothy Ko. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Timothy Ko Today - Breaking & Trending Today

COMP SERVICES (CMPS), Mind Cure Health (MCURF), MIND MEDICINE MINDMED by MIND MEDICINE MINDMED INC. (MMEDF), MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC. (MYCOF) - Psyched: Compass Launches Center Of Excellence, Entheon Purchases HaluGen, Atai Buys Majority Stake In Recognify - Vimarsana News

COMP SERVICES (CMPS), Mind Cure Health (MCURF), MIND MEDICINE MINDMED by MIND MEDICINE MINDMED INC. (MMEDF), MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC. (MYCOF) - Psyched: Compass Launches Center Of Excellence, Entheon Purchases HaluGen, Atai Buys Majority Stake In Recognify

Compass Launches Center Of Excellence Compass Pathways (NASDAQ:CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland. This “clinic model” will study and build the best therapy models for psychedelics treatment and work as a site for clinical trials as well as a laboratory for innovation. It will also explore research around COMP360, Compass’ psilocybin drug candidate. Scott Aaronson MD, Director of Clinical Research at Sheppard Pratt, will lead the center. “Sheppard P...

Entheon Acquires Pre-Testing Genetics Platform For Psychedelic Treatment - Vimarsana News

Entheon Acquires Pre-Testing Genetics Platform For Psychedelic Treatment

 HaluGen Life Sciences Inc. in an all-stock transaction. Entheon acquired 100% of HaluGen in exchange for 5.1 million Entheon shares. Why Genetic Testing Is Important: Psychedelic compounds have gained significant attention in recent years for their potential to treat multiple mental health conditions including major depressive disorder, anxiety, PTSD and addiction.  However, psychedelic drugs have been found to trigger psychotic episodes in individuals with a genetic predisposition to conditions in the psychotic spectrum, like schizophrenia and bipolar I or II disorders.  HaluGen is att...

Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc. - Vimarsana News

Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.

Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc. Vancouver, British Columbia--(Newsfile Corp. - January 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (" Entheon" or the " Company") is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. (" HaluGen"), a biotech company in the business of developing and commercializing a pre-screening test to identify genetic markers predictive of an individual's reaction to hallucinogenic drugs. The Company acquired 100% of the issued and outstanding common shares in the capita...

Entheon Biomedical Corp.: Entheon Biomedical Engages Star Finance GmbH for Investor Relations - Vimarsana News

Entheon Biomedical Corp.: Entheon Biomedical Engages Star Finance GmbH for Investor Relations

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic

Entheon Biomedical Corp.: Entheon Biomedical Announces Private Placement - Vimarsana News

Entheon Biomedical Corp.: Entheon Biomedical Announces Private Placement

Entheon Biomedical Corp.: Entheon Biomedical Announces Private Placement Entheon" or the " Company") announces that it is proceeding with a fully allocated, non-brokered private placement financing of 4,266,997 Units (the "Units") at a price of CDN$0.75 per Unit for gross proceeds of CDN$3,200,247.75 (the "Placement"). This placement is fully subscribed by strategic investors and is expected to close on December 23rd. Each Unit will consist of one common share in the capital of the Company (a "Share") and one-half of one non-transferable share purchase warrant. Each whole Warrant (a "Warrant...